Schering Will Audit Compliance With Anti-Bribery Law Under SEC Settlement
Executive Summary
Schering-Plough will retain an independent consultant to review its compliance with the Foreign Corrupt Practices Act as part of a $500,000 settlement with the Securities & Exchange Commission
You may also be interested in...
SEC, DoJ Beef Up Investigation of Corporate Bribery & Corruption Overseas
Pharma companies have been battered by government and congressional investigations of their domestic marketing practices. They now face increased scrutiny on another front as the Department of Justice and the Securities and Exchange Commission are stepping up their investigation of corporate corruption and bribery abroad
SEC, DoJ Beef Up Investigation of Corporate Bribery & Corruption Overseas
Pharma companies have been battered by government and congressional investigations of their domestic marketing practices. They now face increased scrutiny on another front as the Department of Justice and the Securities and Exchange Commission are stepping up their investigation of corporate corruption and bribery abroad
Pharma CEO Mission Is Defined By Complexity, Products And Trust – Hassan
The explosion in pharmaceutical industry partnerships is one reason that managing "complexity" is a critical core competency for industry leaders, Schering-Plough CEO Fred Hassan told the Pharma, Biotech & Device Colloquium in Princeton, N.J. June 7